News

Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.

A study by Kelvin Chan, MD, PhD, and colleagues compared the efficacy of registrational randomized controlled trials vs the effectiveness in the real world for patients receiving standard of care regimens for multiple myeloma.

Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.

A 10-year trial follow-up indicated that the exclusion of involved-node radiotherapy was correlated with lower progression-free survival among ePET-negative patients with localized Hodgkin lymphoma.

An analysis conducted by Alexandra Leary, MD, and colleagues investigated the safety and efficacy of lurbinectedin after its recent approval by the FDA for patients with advanced solid tumors.

Updated phase 1b results from the CAPItello-292 study demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive, HER2-negative advanced breast cancer.

Identifying specific gene mutations at diagnosis through a mutation associated with progression, or MAP, signature, and/or m7-FLIPI model can offer predictive value among patients with follicular lymphoma, according to a clinicogenomic...

Based on results from the KEYNOTE-A18 trial, the FDA has approved pembrolizumab plus chemoradiotherapy for patients with FIGO 2014 Stage III to IVA cervical cancer.

The FDA has granted approval to enfortumab vedotin-ejfv with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

According to results from the CANOPY-1 trial, the addition of canakinumab to first-line pembrolizumab plus chemotherapy did not prolong PFS or OS among patients with advanced or metastatic non-small cell lung cancer who do not harbor ALK or...